Loading
Latest filing published 30 Sept 2026 for 엘앤씨바이오. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
이환철 (chief executive) discloses dealings in 엘앤씨바이오 to DART (FSS). In total, 64 filings cover trades dated from 23 February 2021 to 30 September 2026.
In open-market terms, that means 40 purchases on one side and 9 sales on the other. The totals exclude 49 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show no purchases and 3 sales.
The 39 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 30 September 2026, reports an open-market sale in 엘앤씨바이오. The latest purchase dates back some time: it was published 748 days ago, on 30 September 2024. Filings reach the DART (FSS) feed a median of 3 days after the trade. This delay matters because a trade only becomes useful information once it is public. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 64 declarations